EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Vuno Inc. (338220) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Vuno Inc. KRW 1,690, price KRW 5,570, upside -69.7%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

VI Thin data Sep 24, 2026

Vuno Inc.

338220 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,690 KRW · Strongly overvalued (−70%)
!Quality 42/100
!Expensive Growth (revenue 5y +94.3 %/yr)
!Loss-making · -19.4% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (1/8)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Vuno Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

65,500 KRW 4,320 KRW Fair Value 1,690 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 4,320 KRW – 65,500 KRW · fair‑value band 1,115 KRW – 2,112 KRW · the 5,570 KRW price screens above the 1,690 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Vuno in your weekly email

Every Wednesday you see whether Vuno is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis.

Show more

Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis. It also offers BoneAge, an AI diagnostic software for bone age assessment; DeepBrain, a brain parcellation for the quantitative analysis of neurodegenerative diseases and other neurological disorders; chest X-ray, a diagnostic support system for abnormalities in chest x-ray; fundus AI, an AI-based screening solution for various abnormalities in the fundus of the eye; DeepCARS, an AI-based cardiac arrest risk management system; and LungCT AI, an AI-based pulmonary lung nodule detection and reporting system. In addition, the company provides medical products under HATIV brand, such as HATIV K30, a kiosk-type medical device that measures electrocardiograms; HATIV P30, a medical ECG device; HATIV BP30, an automatic blood pressure monitoring device; and HATIV TP50T, an ear infrared thermometer device. The company was founded in 2014 and is headquartered in Seoul, South Korea.

Stock analysis

Vuno Inc. (338220) currently trades at 5,570 KRW, while our model-based Fair Value estimate is 1,690 KRW, implying the stock looks roughly 229.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 1,115 KRW (bear) to 2,112 KRW (bull), the price of 5,570 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Vuno Inc. reported revenue of 34.8B KRW in FY2025 versus 2.2B KRW in FY2021, a compound +98.4%/yr. Reported net income was −5.8B KRW in FY2025.

Key figures

Market cap 103B KRW (≈ $75.9M) · P/S ratio 3.10 · Net margin −16.6% · Return on equity −18.9% · Return on assets (EBIT) −43.5% · Operating margin −67.9% · Revenue (TTM) 33.4B KRW · Revenue growth (YoY) −19.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −70%, 338220 screens richer than that median.

Fair Value models

Bear 1,115 KRW Fair Value 1,690 KRW Bull 2,112 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,290 KRW 1,728 KRW 2,579 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,290 KRW 1,728 KRW 2,579 KRW 54

Open the full fair value analysis →

Notify me when 338220 reaches fair value

Put 338220 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 45 · Market factors (momentum, volatility) 12

Profitability 29
Margins and returns on capital today
Quality Growth 90
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 44
Disciplined investing over empire-building
Low Volatility 33
Calm price path (market factor)
Momentum 4
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 39
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+34.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+94.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−773.3% (2020) → −14.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

338220 screens 230% overvalued. Compare with Veeva Systems Inc →

Compare Vuno Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 133 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −70% · Bottom 25%
Profitability
Return on assets −7% · Below median
Net margin (TTM) −19% · Below median
Operating margin (TTM) −68% · Bottom 25%
Growth and dividend
Revenue growth −20% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 4
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 5
HEALTH (low debt)98 · sector 98
DIVIDEND (yield)0 · sector 48

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $270.75 $297.83 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vuno Inc. · Fair Value
1,690 KRW −230%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Vuno Inc. Fair Value". https://www.fairvalue-calculator.com/stock/338220

Frequently asked questions

Is Vuno Inc. (338220) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,690 KRW versus a price of 5,570 KRW, about −70% upside (overvalued).
What is the fair value of 338220?
Our model-based fair value for Vuno Inc. is 1,690 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,570 KRW.
What is the quality score of 338220?
Vuno Inc. has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vuno Inc. (338220)?
Our model-based price target is the fair value of 1,690 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1,115 KRW, optimistic scenario 2,112 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Vuno Inc. stock forecast for 2026?
Our models put fair value at 1,690 KRW, about −70% upside versus a price of 5,570 KRW (overvalued). Cautious scenario 1,115 KRW, optimistic scenario 2,112 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Vuno Inc. (338220)?
Vuno Inc. reported trailing-twelve-month revenue of about 33.4B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Vuno Inc. (338220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vuno Inc. it is 1,690 KRW per share (as of Sep 24, 2026), against a price of 5,570 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Vuno Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 338220 trades above its calculated fair value: price 5,570 KRW, fair value 1,690 KRW, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 338220?
No. The price is what the market pays today (5,570 KRW); the fair value is what the company's own numbers justify (1,690 KRW). For Vuno Inc. the two are 3,880 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Vuno Inc. worth?
The market values Vuno Inc. at about 103B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,570 KRW; our models calculate a fair value of 1,690 KRW per share.
What do the bullish and bearish scenarios say about 338220?
Our models span a range for Vuno Inc.: cautious scenario 1,115 KRW, base 1,690 KRW, optimistic 2,112 KRW per share (as of Sep 24, 2026, price 5,570 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vuno Inc. (338220)?
Balance-sheet figures for Vuno Inc. (as of Sep 24, 2026): return on equity −18.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 338220 from its 52-week high?
Vuno Inc. trades at 5,570 KRW, about 80% below its 52-week high of 27,600 KRW and 29% above the low of 4,320 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,690 KRW is for.
Which stocks are comparable to Vuno Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vuno Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 5,570 KRW, calculated fair value 1,690 KRW (−70%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 338220 calculated?
We run Vuno Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,690 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Vuno Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vuno Inc. (338220)?
The closing price on Sep 23, 2026 was 5,570 KRW. Our model-based fair value is 1,690 KRW, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vuno Inc. right now?
The price sits above even our optimistic bull case (2,112 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,115 KRW to 2,112 KRW) leaves room in how you read the outcome.

Key figures of Vuno Inc.

How large is the market capitalisation of Vuno Inc. (338220)?
The market capitalisation of Vuno Inc. is 103B KRW (≈ $75.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vuno Inc. (338220)?
The price-to-sales ratio of Vuno Inc. is 3.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Vuno Inc. (338220)?
The net margin of Vuno Inc. is −16.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vuno Inc. (338220)?
The return on equity (ROE) of Vuno Inc. is −18.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vuno Inc. (338220)?
On an EBIT basis the return on assets of Vuno Inc. is −43.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vuno Inc. (338220)?
The operating margin of Vuno Inc. is −67.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vuno Inc. (338220)?
Revenue at Vuno Inc. is growing −19.7% versus a year earlier (3y avg +61.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vuno Inc. (338220) generate?
The free cash flow of Vuno Inc. is −5.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vuno Inc. (338220) carry?
The net debt of Vuno Inc. is 1.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vuno Inc. in the live analysis

One click puts Vuno Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.